Non-CML Myeloproliferative Diseases, An Issue of Hematology/Oncology Clinics of North America
Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.
|Author Information||By Ross Levine, MD, Memorial SloHuman Oncology and Pathogenesis Program. Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.an-Kettering Cancer Center|
|Stock Status||In Stock|
Write Your Own Review